Newsletters


Filter by volume

Agenus on Twitter

A rewarding initiative born from visionary Mary Stutts! Thank you to our interns & our leaders @Agenus_Bio Berkeley for building the next generation of innovators & disruptors. Great coverage @abc7newsbayarea! twitter.com/jbuell01/statu…

$AGEN newsletter is now available: Balstilimab Monotherapy and Balstilimab plus Zalifrelimab Trials Presented at ESMO: agenusbio.com/wp-content/upl… #ESMO20 #oncology #immunotherapy #cervicalcancer

Replay of discussion of $AGEN #ESMO20 data presentation hosted by @Phipps_MC @WilliamBlair with Dr. O'Malley @OSUCCC_James is now available and can be accessed here: williamblair.zoom.us/rec/play/B24AG… #oncology #immunotherapy #cervicalcancer twitter.com/Agenus_Bio/sta…

Agenus (AGEN) Initiates Rolling BLA Submission of Balstilimab #fightcancer #ESMO20@Agenus_Biotwitter.com/morgan_buell/s…

WATCH NOW: the inaugural episode of "18 Minutes with..." @MediaJerNYC @sciam and $AGEN President & COO, Dr. Jennifer Buell (@jbuell01). Learn about disruptive approaches to #cancer, #COVID19, & #Immunotherapy twitter.com/MediaJerNYC/st…

@beilis_jay Only registered attendees can listen to the conference live. A replay of the conference can be accessed at the $AGEN website at investor.agenusbio.com/events-and-pre…

Dr. O’Malley and members of the $AGEN management team will discuss the data presented at #ESMO20 and next steps for balstilimab +/- zalifrelimab at a webcast hosted by Dr. Matt Phipps of William Blair today at 2:30pm ET. See details here: investor.agenusbio.com/news-releases/… #oncology

test Twitter Media - Dr. O’Malley and members of the $AGEN management team will discuss the data presented at #ESMO20 and next steps for balstilimab +/- zalifrelimab at a webcast hosted by Dr. Matt Phipps of William Blair today at 2:30pm ET. See details here: https://t.co/1QtBwTAjKc #oncology https://t.co/v8dNHkNnjT

Excellent presentation by @lillian_siu on MK-4830, a first-in-class, ILT4 targeting antibody discovered @Agenus_Bio and partnered with @Merck. Siu described how MK-4830 reprograms tumour-associated macrophages, relieving myelosuppression & enhancing T cell activity. twitter.com/myESMO/status/… Retweeted by Agenus Inc. ($AGEN)

In patients with recurrent/metastatic cervical cancer, the PD-1 inhibitor balstilimab monotherapy or combined with the CTLA-4 inhibitor zalifrelimab demonstrated promising objective response rates no matter the patients PD-L1 status. #ESMO20 twitter.com/TargetedOnc/st…

Cervical cancer claims the lives of more then 4500 young women each year; @Agenus_Bio is committed to change this current reality. #CervicalCancer #Immunotherapy #ESMO20 twitter.com/JohnNosta/stat…

BREAKING! In metastatic cervical #cancer, Agenus advances efficacy with their complementary CTL4 and PD1 combo—27% response vs monotherapy 14% with #keytruda. @agenus_bio @jbuell01 #oncology #ESMO2020 Retweeted by Agenus Inc. ($AGEN)

$AGEN bal +/- zal at #ESMO show ORR of 19 & 27% in PD-L1 (+); PD-L1 (-) responders & favorable safety with treatment-related d/c 3.7 & 6.5% investor.agenusbio.com/news-releases/…

test Twitter Media - $AGEN bal +/- zal at #ESMO show ORR of 19 & 27% in PD-L1 (+); PD-L1 (-) responders & favorable safety with treatment-related d/c 3.7 & 6.5%  https://t.co/OJQGyMv8E4 https://t.co/0kGHwvtSga

Agenus Initiates Rolling BLA Submission of Balstilimab for Recurrent/Metastatic Cervical Cancer investor.agenusbio.com/news-releases/…

$AGEN's presentation is one of the many affected by this delay twitter.com/myESMO/status/…

Agenus Presents Results from Two Large Cervical Cancer Trials at ESMO investor.agenusbio.com/news-releases/…

$AGEN's late-breaking ESMO abstract has been released and can be viewed here under Gynaecological cancers 2: cslide.ctimeetingtech.com/esmo2020/atten…. The countdown to $AGEN's ESMO presentation begins! #ESMO2020 #oncology #immunotherapy

test Twitter Media - $AGEN's late-breaking ESMO abstract has been released and can be viewed here under Gynaecological cancers 2: https://t.co/r48TE5Njix. The countdown to $AGEN's ESMO presentation begins! #ESMO2020 #oncology #immunotherapy https://t.co/Zn1gkNJCNx

Dr. Jennifer Buell Speaks Live at Scientific American Inaugural Fireside Chat Series 18 Minutes With investor.agenusbio.com/news-releases/…